RRM1 and non-small cell lung carcinoma: Finally, non-small cell lung cancer patients with low expression of the M1 subunit of RR (RRM1) significantly benefited from gemcitabine/cisplatin neoadjuvant chemotherapy (Rosell et al, 2004), while resistance to gemcitabine was observed both in RRM1 and RRM2 overexpressing cells (Goan et al, 1999; Davidson et al, 2004).